Catalent-Repligen Merger ‘Seems Unlikely,’ This Analyst Says
Yesterday, Catalent Inc (NYSE:CTLT) announced to acquire Metrics Contract Services for $475 million. Keybanc notes that the deal strengthens CTLT’s oral delivery…
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent…
Senate Finance Committee Expands Amgen’s Tax Probe: Report
Senator Ron Wyden sent a letter to Amgen Inc (NASDAQ: AMGN) asking what methods the company has used to pay an average effective tax rate of around 12% over the past four years.
Relief And Acer Therapeutics Secures Orphan Drug Designation From European Union For Metabolic Disorder Candidate
The European Commission has granted orphan medicinal product designation in the EU to Relief Therapeutics and Acer Therapeutics’ (NASDAQ: ACER) lead asset ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD).
FDA Approves Expanded Use Of Roche’s Influenza Treatment
The FDA has approved the expanded use of Roche Holding AG’s (OTC:RHHBY) Xofluza (baloxavir marboxil). The medicine has been approved to treat…
4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment
4D Molecular Therapeutics Inc (NASDAQ:FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing…
Rapid Micro Rejects Takeover Deal, Adopts Poison Pill To Thwart Investor
Rapid Micro Biosystems Inc (NASDAQ: RPID) has initiated a review of strategic alternatives and has retained Morgan Stanley & Co. LLC as…
Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint
Aptinyx Inc. (NASDAQ: APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.
The Phase 2b clinical study was designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia.
Daiichi-AstraZeneca’s Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
The FDA has approved Daiichi Sankyo (OTC:DSNKY) and AstraZeneca plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC)…